TScan Therapeutics, Inc. (TCRX): Form 8-K filed 2026-09-02

Accepted by EDGAR

2026-09-02 07:22 ET

Event date

2026-08-27

Accession no.

0001193125-26-379343

Original filing

SEC EDGAR filing index

Items reported

• Item 2.05: Cost Associated with Exit or Disposal Activities
  The company committed to an exit or disposal plan, such as a restructuring, facility closure or workforce reduction, under which it expects to incur material charges.
• Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  The company received notice from its exchange that it does not satisfy a continued listing rule (for example a minimum bid price or filing requirement), or it decided to delist or transfer its listing.
• Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
  A director or a named officer (such as the CEO or CFO) left or was appointed, or certain executive compensation arrangements were adopted or changed.
• Item 7.01: Regulation FD Disclosure
  The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed".
• Item 8.01: Other Events
  A voluntary disclosure of an event the company considers important to security holders that no other Item covers, such as a dividend declaration, a buyback program, litigation updates or product news.
• Item 9.01: Financial Statements and Exhibits
  Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

Documents

This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.